Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

America Great Health

Company price
0.0002 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
150000
Market Cap
4.23M

Momentum Score

…

America Great Health operates as a biotechnology company in the United States. The company focuses on the research and development of protein and peptide small molecular drugs; and manufacture and sale of AI cloud computing-based diagnostic and medical devices, cell therapy, and re-generational medicine and supplements. The company was formerly known as Crown Marketing and changed its name to America Great Health in March 2017. America Great Health is based in Alhambra, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.36M
Revenue Per Share
-
Gross Profit TTM
0.25M
Debt / Equity
-0.50
ROE
-
Net Debt
2.80M
ROCE
11.30%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -0.72M -1.23M -0.78M -0.78M -0.27M
Minority interest - 0.00M 0.01M 0.02M 0.06M
Net income -0.72M -1.22M -0.76M -0.76M -0.27M
Selling general administrative 0.67M 0.86M 0.66M 0.66M 0.29M
Selling and marketing expenses 0.05M 0.10M 0.00M 0.00M 0.09M
Gross profit 0.34M 0.17M 0.17M 0.17M 0.05M
Reconciled depreciation - 0.01M 0.01M 0.01M 0.01M
Ebit -0.40M -0.78M -0.46M -0.46M -0.24M
Ebitda -0.38M -0.77M -0.45M -0.45M -0.25M
Depreciation and amortization 0.01M 0.01M 0.01M 0.01M -0.01M
Operating income -0.38M -0.78M -0.49M -0.49M -0.24M
Other operating expenses 0.77M 1.08M 0.70M 0.70M 0.44M
Interest expense 0.34M 0.44M 0.32M 0.32M 0.02M
Interest income - 0.00M 0.00M 0.00M 0.00M
Net interest income - -0.34M -0.44M -0.32M -0.19M
Income tax expense - - 0.34M 0.34M 0.02M
Total revenue 0.39M 0.29M 0.20M 0.20M 0.20M
Total operating expenses 0.72M 0.95M 0.66M 0.66M 0.29M
Cost of revenue 0.05M 0.12M 0.04M 0.04M 0.14M
Total other income expense net -0.34M -0.44M -0.28M 0.03M -0.03M
Net income from continuing ops - -0.72M -1.23M -0.78M -4.92M
Net income applicable to common shares - - - -0.76M -4.87M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 0.30M 0.32M 0.30M 0.30M 0.62M
Other current assets 0.03M 0.03M 0.02M 0.02M 0.02M
Total liab 6.05M 5.64M 4.82M 4.82M 1.09M
Total stockholder equity -5.74M -5.23M -4.53M -4.45M -0.47M
Other current liab 4.39M 1.47M 0.67M 0.67M 0.32M
Capital stock - 0.00M 0.00M 0.00M 0.00M
Retained earnings -10.78M -10.25M -9.18M -9.18M -3.56M
Other liab - - - 0.61M 0.38M
Other assets - - - 0.02M 0.02M
Cash 0.04M 0.05M 0.05M 0.05M 0.40M
Total current liabilities 3.82M 3.59M 3.09M 3.09M 0.43M
Current deferred revenue 0.08M 0.06M 0.22M 0.22M 0.16M
Net debt 2.80M 2.43M 1.82M 1.82M 0.31M
Short term debt 0.65M 0.63M 0.75M 0.75M 0.05M
Short long term debt - 0.60M 0.61M 0.71M 0.18M
Short long term debt total 2.84M 2.48M 1.87M 1.87M 0.71M
Other stockholder equity 10.16M 5.02M 4.73M 4.73M 3.09M
Property plant equipment - - - 0.10M 0.12M
Total current assets 0.24M 0.23M 0.18M 0.18M 0.48M
Net tangible assets - - - -4.45M -3.80M
Net receivables - 0.06M 0.06M 0.00M 0.06M
Long term debt - 2.22M 1.83M 1.12M 1.03M
Inventory 0.16M 0.08M 0.11M 0.11M 0.01M
Accounts payable 1.49M 1.44M 1.45M 1.45M 0.06M
Accumulated other comprehensive income -0.00M -0.00M -0.00M -0.00M 0.00M
Non currrent assets other 0.01M 0.01M 0.01M 0.02M 0.02M
Non current assets total 0.07M 0.10M 0.12M 0.12M 0.14M
Capital lease obligations - 0.03M 0.04M 0.04M 0.09M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - 0.00M -0.04M -0.02M
Change to liabilities - - - 0.08M 1.54M
Total cashflows from investing activities - - -0.04M -0.04M -0.02M
Net borrowings - 0.14M -0.11M 0.70M 1.07M
Total cash from financing activities 0.32M 0.62M 0.79M 0.79M 0.74M
Change to operating activities - - - -0.09M 0.51M
Net income -0.72M -1.23M -0.76M -0.78M -0.27M
Change in cash -0.01M 0.00M -0.01M -0.01M 0.40M
Begin period cash flow 0.05M 0.05M 0.06M 0.06M 0.00M
End period cash flow 0.04M 0.05M 0.05M 0.05M 0.40M
Total cash from operating activities -0.33M -0.62M -0.75M -0.75M -0.33M
Issuance of capital stock - 0.10M 0.12M 0.09M 0.10M
Depreciation 0.01M 0.01M 0.01M 0.01M 0.01M
Dividends paid - 0.00M 0.00M - -
Change to inventory -0.08M 0.02M 0.01M 0.01M -0.01M
Change to account receivables 0.06M -0.06M 0.00M 0.00M -0.00M
Other cashflows from financing activities 0.32M 0.62M -0.15M 0.70M 0.74M
Change to netincome - - - -0.01M 1.31M
Capital expenditures 0.00M 0.00M 0.04M 0.04M 0.01M
Change in working capital 0.46M 0.50M -0.09M -0.01M -0.08M
Stock based compensation - 0.12M 0.07M 0.00M 0.00M
Other non cash items 0.37M -0.02M -0.06M 0.02M 0.01M
Free cash flow -0.33M -0.62M -0.80M -0.80M -0.34M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AAGH
America Great Health
-
-%
0.00 - - 11.64 358698.71 20.16 7.21
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

America Great Health

America Great Health operates as a biotechnology company in the United States. The company focuses on the research and development of protein and peptide small molecular drugs; and manufacture and sale of AI cloud computing-based diagnostic and medical devices, cell therapy, and re-generational medicine and supplements. The company was formerly known as Crown Marketing and changed its name to America Great Health in March 2017. America Great Health is based in Alhambra, California.

1609 W. Valley Blvd., Alhambra, CA, United States, 91803

888 988 1333

5

Name Title Year Born
Mr. Mike Qingkun Wang CEO, Pres, CFO, Sec. & Chairman 1955
Mr. Qinghua Chen CPA, CPA Chief Financial Officer 1963
Mr. David Liu Chief Operating Officer NA
David Tsai Chief Scientist NA
Mr. Mike Qingkun Wang CEO, President, CFO, Secretary & Chairman of the Board 1955

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…